Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

NC Biz Court Bulletin: COVID Coverage, A Suspect Signature No Photo Available

Hayley Fowler

The North Carolina Business Court has rounded the corner into fall with insurance disputes over COVID-19 coverage at a chain of outlet... (more story)

MAHA Insider Talks 'Fever Point' For Healthcare No Photo Available

Yeji Jesse Lee

A MAHA insider says the healthcare industry should be prepared amid a massive cultural shift on health issues.

Healthcare Laws This Week: Drug Pricing, AI And Aid In Dying No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at a proposal by congressional Democrats to scale back Medicare price negotiation exemptions for so-... (more story)